AsepticSure Patent Protection Program Expanded -- Superbugs In Five Countries Get Nervous

SAN FRANCISCO, Jan. 9, 2012 /PRNewswire/ -- Medizone International, Inc. (MZEI:OB) (MZEI:QB), the research and development company behind AsepticSure disinfection technology, announced today that filings of its recently granted lead patent application (Canadian Patent No 2735739) have been completed in the United States, Mexico, Brazil, China and Japan.

AsepticSure's proven efficacy against a vast spectrum of pathogenic bacteria, fungi, spores and viruses now paves the way for its use in large-scale reductions of hospital acquired infections (HAIs) in medical centers, health care organizations and hospitals around the world.

It is also the only disinfection technology in existence that has reliably and repeatedly demonstrated in peer-reviewed research, a 100% kill-rate with deadly pathogens such as C-difficile and MRSA, the root source of superbug infections, globally.

Medizone's lead patent was granted on November 22, 2011 by the Canadian Intellectual Property Office (patent office) for processes and systems relating to the platform technology. 

Medizone Board Chairman and CEO, Edwin Marshall, added, "Shareholders should be highly encouraged by the continued success of our intellectual property protection program. Additional filings are currently in process for all of the European Union, Great Britain, India, Korea, Australia and South Africa. These filings will be submitted over the next few weeks.

For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202    E: [email protected] 

Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

For more information, visit: www.medizoneint.com
Email: [email protected]

SOURCE Medizone International, Inc.